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Abstract
Background: While NF-κB p50 function is impaired in central nervous system disease, aging in non-CNS tissues,
and response to reactive oxygen species, the role of NF-κB p50 in aging-associated microglial pro-inflammatory
priming is poorly understood.
Methods: Male NF-κB p50+/+ and NF-κB p50−/− mice at three different ages (1.5–3.0 month old, 8.0–11.0 month old,
and 16.0–18.0 month old) were treated with LPS (5 mg/kg, IP) to trigger peripheral inflammation, where circulating
cytokines, neuroinflammation, microglia morphology, and NF-κB p50/p65 function in brain tissue were determined
3 h later.
Results: Peripheral LPS injection in 9-month-old C57BL/6 mice resulted in lower NF-κB p50 DNA binding of nuclear
extracts from the whole brain, when compared to 3-week-old C57BL/6 mice, revealing differences in LPS-induced
NF-κB p50 activity in the brain across the mouse lifespan. To examine the consequences of loss NF-κB p50 function
with aging, NF-κB p50+/+ and NF-κB p50−/− mice of three different age groups (1.5–3.0 month old, 8.0–11.0 month
old, and 16.0–18.0 month old) were injected with LPS (5 mg/kg, IP). NF-κB p50−/− mice showed markedly elevated
circulating, midbrain, and microglial TNFα when compared to NF-κB p50+/+ mice at all ages. Notably, the
16.0–18.0-month-old (middle aged) NF-κB p50−/− mice exhibited synergistically augmented LPS-induced serum
and midbrain TNFα when compared to the younger (1.5–3.0 month old, young adult) NF-κB p50−/− mice. The
16.0–18.0-month-old LPS-treated NF-κB p50−/− mice also had the highest midbrain IL-1β expression, largest
number of microglia with changes in morphology, and greatest elevation of pro-inflammatory factors in isolated adult
microglia. Interestingly, aging NF-κB p50−/− mice exhibited decreased brain NF-κB p65 expression and activity.
Conclusions: These findings support that loss of NF-κB p50 function and aging in middle-aged mice may interact to
excessively augment peripheral/microglial pro-inflammatory responses and point to a novel neuroinflammation
signaling mechanism independent the NF-κB p50/p65 transcription factor in this process.
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Background
As resident sentinels surveying the central nervous sys-
tem (CNS) environment [1], electricians regulating syn-
aptic communication [2], and innate immune cells of
the brain [3], microglia are essential to CNS mainten-
ance and health [4]. Microglia respond to a host of stim-
uli including cellular damage, environmental toxins, and
pathogens [5] with a carefully orchestrated activation re-
sponse. Neuropathology and CNS disease is believed to
occur when the microglial pro-inflammatory response is
exacerbated and unregulated [5–7], which is linked to
microglial priming [8]. Microglia have long been impli-
cated in late-onset neurodegenerative diseases [9] that
are closely related to aging [10], such as Parkinson’s
disease.
Current theory holds that a phenotypic shift in micro-
glia towards a more reactive primed state occurs as the
brain ages [11–14]. While there are some conflicting
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reports in the literature [15], aged microglia challenged
with an innate immune stimulus, such as peripheral
LPS, are generally reported to exhibit a significantly
more pronounced pro-inflammatory response [16],
which is referred to as priming. In fact, even without a
distinct innate immune trigger, the aged brain is re-
ported to display heightened basal levels of pro-inflam-
matory cytokines, such as TNFα, IL-1β, and IL-6 [17–
19] along with lower levels of alternative activation and
anti-inflammatory factors, including IL-4 [20], IL-4 re-
ceptor [21], IL-10 [19], fractalkine [22, 23], and CD200
[24]. The mechanisms underlying the changing neuroin-
flammation responses across the lifespan are largely
undefined.
While the causes driving the enhanced sensitivity of
aging microglia to proinflammatory stimuli are poorly
understood, age-related microglial priming is predicted
to be an interaction between the microglial responses to
increasingly deleterious changes in the CNS environ-
ment [25] and intrinsic microglial characteristics associ-
ated with aging [12]. For example, several factors are
implicated in the process of age-induced microglial
priming, including upregulation of innate immune re-
ceptors on microglia responsible for the detection of
pro-inflammatory stimuli [12, 25], enhanced peripheral
inflammation/circulating cytokine production that trans-
fers to the brain to impact neuroinflammation [26], and
elevated states of oxidative stress in the aged brain [27–
29]. However, the intrinsic signaling mechanisms that
shift microglia into a primed state as the brain ages re-
main unclear.
Previous reports point to NF-κB p50 as an essential
pleiotropic regulator of the pro-inflammatory response
[30], where loss of NF-κB p50 function due to reactive
oxygen species (ROS) [7] or genetic deletion resulted in
dysregulated microglial activation culminating in chron-
ically elevated TNFα production in the brain [7, 31].
While little is currently known about NF-κB p50 func-
tion in the aged brain, loss of NF-κB p50 function has
been linked to CNS disease, where patients with Lewy
Body Dementia have been documented to express less
NF-κB p50 in the substantia nigra [32]. Mechanistically,
the NF-κB family of transcription factors are essential
regulators of the pro-inflammatory response [33, 34],
where the NF-κB p50/p65 heterodimer is a prototypical
pro-inflammatory transcription factor linked to the initi-
ation of the expression of pro-inflammatory genes [35,
36]. While less intuitive, the NF-κB p50/p50 homodimer
is a repressor of the pro-inflammatory response that is
both constitutively bound and activated with delayed
kinetics to regulate the pro-inflammatory response [35,
36]. Mice that lack functional NF-κB p50 are more sen-
sitive to neurotoxins, display memory deficits [37], show
an aberrant microglia-mediated inflammatory response
in a rodent Alzheimer’s disease model [31], exhibit a
dysfunctional kinetic response of the microglial
pro-inflammatory response, and are vulnerable to
chronic neuroinflammation [7]. Global knockout of
NFκB1, the gene that encodes NF-κB p50, causes a loss
of NF-κB p50 function in all cells which can obscure the
assessment of immune-mediated neurotoxicity, depend-
ing on the model, where NF-κB p50−/− mice are pro-
tected from ischemia-induced neuronal apoptosis [38].
Importantly, NFκB1 knockout mice demonstrate chronic
low-grade inflammation across their lifespan and accu-
mulate telomere dysfunction and prematurely senescent
cells in the periphery, supporting that loss of NF-κB p50
function may accelerate aging [39–42]. Further, in per-
ipheral tissues, NF-κB p50 function is reported to de-
cline with age [40, 42]. Thus, while NF-κB p50 is
associated with aging/cellular senescence, regulates the
microglial pro-inflammatory response, and has CNS ef-
fects, the role of NF-κB p50 in microglial aging is
unknown.
Here, to begin to explore the role of NF-κB p50 in
microglial pro-inflammatory priming with age, we ad-
dressed (1) the impact of aging on NF-κB p50 function
in the brain and (2) the effect of loss of NF-κB p50 func-
tion on LPS-induced circulating cytokines, neuroinflam-
mation, and the production of pro-inflammatory factors
in microglia in the aging brain. We demonstrate that the
brain NF-κB p50 response to peripheral inflammation
changes across the lifespan and that microglial priming
and neuroinflammation in middle-aged mice is synergis-
tically amplified by the loss of NF-κB p50 function and
aging.
Methods
Reagents
Lipopolysaccharide (0111,B4, lot 050M4100) was ob-
tained from Sigma-Aldrich (St. Louis, MO). Cell culture
reagents were purchased from Invitrogen (Carlsbad, CA)
and Corning (Corning, NY). Phosphatase inhibitor and
HALT protease inhibitor were acquired from Thermo
Fisher Scientific (Rockford, IL). All other reagents were
purchased from Sigma-Aldrich Chemical Company (St.
Louis, MO).
Animals
NF-κB p50-deficient mice (B6.Cg-Nfkb1 tm1Bal/J, NF-κB
p50−/−) and C57BL/6J (NF-κB p50+/+) mice were pur-
chased from Jackson Laboratories (Bar Harbor, Maine)
and maintained in a strict pathogen-free environment.
NF-κB p50−/− mice have a targeted mutation of exon 6
in the Nfkb1 gene that results in non-functional NF-κB
p105 and NF-κB p50 proteins due to a truncated peptide
that prevents dimerization with NF- κB subunits and
DNA binding [43]. The NF-κB p50−/− mutation is
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maintained in the C57BL/6J background; therefore,
C57BL/6J (NF-κB p50+/+) mice were used as controls.
National Institutes of Health guidelines for breeding,
housing, and experimental use of the animals were
strictly followed.
In vivo LPS treatment
Male NF-κB p50+/+ and NF-κB p50−/− mice of three dif-
ferent age groups (1.5–3.0 month old, 8.0–11.0 month
old, and 16.0–18.0 month old) received a single intraper-
itoneal (IP) injection of LPS (5 mg/kg) or equivalent vol-
ume of vehicle (0.9% saline). The administration of the
single LPS (5 mg/kg, IP) injection is a murine Parkin-
son’s disease model of chronic neuroinflammation that
persists across the lifespan of the mouse and culminates
in delayed and progressive DA neuron loss in the sub-
stantia nigra that begins at 7 months after the injection
[29, 44]. Based on our previous work, this LPS dose
causes peripheral inflammation that rapidly transfers to
the brain causing microglial activation in the substantia
nigra in young adult NF-κB p50+/+ and NF-κB p50−/−
mice, that is evident at 3 h after injection [7]. As such,
similar to our prior work [7], circulating cytokines,
microglial activation, and midbrain (which contains the
substantia nigra)/whole brain neuroinflammation were
assessed at 3 h post-injection, where protein, mRNA, or
morphological analyses were performed on serum and
brain tissue following collection.
Immunohistochemistry
Immunohistochemistry was performed on 40-μm cor-
onal sections of the midbrain region as described previ-
ously [7]. Briefly, free-floating brain slices were stained
with anti-tyrosine hydroxylase (TH, 1:1000) rabbit poly-
clonal antibody (Millipore Billerica, MA) to visualize
dopaminergic neurons to confirm that sectioned samples
across mice were in the same frame of the substantia
nigra pars compacta (SNpc) and a polyclonal rabbit
anti-ionized calcium-binding adaptor molecule-1 (Iba1,
1:1000) antibody (Wako, Richmond, VA) was used to
identify microglia as previously described. Images were
captured with an Olympus BX51 microscope (Olympus
America, Center Valley, PA) [7].
Nuclear protein extraction and NF-κB p50 and p65 DNA
binding ELISA
A commercially available Nuclear Extract Kit (Active
Motif, Carlsbad, CA) was used to collect nuclear protein
from whole brain tissue, as we have previously reported
[7]. The TransAM NFκB ELISA (Active Motif, Carlsbad,
CA) was used to assess DNA binding based on the abil-
ity of nuclear protein to bind a generic NF-κB DNA con-
sensus site (5′-GGGACTTTCC-3′) immobilized on a 96
well plate according to manufacturer’s instructions.
NF-κB p65 Western blot
Ten micrograms of nuclear extract were electrophoresed
on a 12% SDS-PAGE gel. Samples were transferred to
nitrocellulose membranes by semi-dry transfer, blocked
with 5% nonfat milk for 1 h at 24 °C, followed by incuba-
tion overnight with mouse anti-GAPDH (Millipore, Bil-
lerica, MA, 1:1000) or rabbit anti-NF-κB p65 (SC-372,
Santa Cruz Biotechnology, Dallas, TX, 1:1000) antibodies
at 4 °C. Blots were then incubated with horseradish
peroxidase-linked mouse anti-rabbit (1:2500) or goat
anti-mouse (1:5000) for 1 h (24 °C), and ECL Plus re-
agents (Amersham Biosciences Inc., Piscataway, NJ)
were used as a detection system. Band density was quan-
titated with ImageJ [34] and analyzed as a ratio of
GAPDH and NF-κB p65. Results are reported as a per-
cent increase from control.
Quantitative reverse transcriptase polymerase chain
reaction
Total RNA was extracted from the mouse brain or from
isolated microglia using Trizol (Invitrogen Life Tech-
nologies, Grand Island, NY) according to manufacturer’s
instructions. The RNA was treated with Ambion DNase
I (Invitrogen Life Technologies, Grand Island, NY)
which was subsequently removed with Qiagen RNeasy
RNA Cleanup Kit (Qiagen, Germantown, MD). Reverse
transcription of RNA (0.3–1.0 μg/sample) was performed
with iScript Reverse Transcription Supermix (BioRad,
Hercules, CA) according to manufacturer’s instructions.
SsoFast Evagreen Supermix (BioRad, Hercules, CA) and
500 nM forward and reverse primers were used to carry
out quantitative PCR on a CFX96 (BioRad, Hercules,
CA) real-time PCR detection system, per manufacturer’s
instructions. Cycling parameters were 1 cycle at 95 °C for
5 min and 40 cycles of 95 °C (5 s) and 56 °C (5 s) followed
by a melt curve measurement consisting of 5 s 0.5°C in-
cremental increases from 65 °C to 95 °C. Primer se-
quences used in this study are listed in Table 1.
Adult microglia isolation
Adult microglia isolation was performed as previously
described [7, 45]. Briefly, mice were anesthetized at 3 h
post-injection and perfused with 50mL cold PBS and
microglia were isolated using the Miltenyi Neural Tissue
Dissociation Kit (P), (Miltenyi Biotec, San Diego, CA)
according to manufacturer’s instructions, which results
in 87.0% pure microglia/CD11b positive cells [7].
Tumor necrosis factor α ELISA
The TNFα concentrations in sera and cell culture
media were measured with a commercial ELISA kit
from R&D Systems (Minneapolis, MN), as previously
reported [7, 44].
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Stereology: assessment of microglial activation
The fractionator method of unbiased stereology was uti-
lized to evaluate microglial activation in the SNpc, as
previously described [7, 46]. Briefly, TH-stained coronal
sections located at − 3.14, − 3.26, and − 3.38 mm bregma
were used to delineate the SNpc. A 40× objective was
used to score stages of the changes in microglial
morphology of IBA-1 stained microglia within the
SNpc. Morphological parameters were used to identify
four distinct morphology classifications (0–3) as pre-
viously described [7, 46]. Samples were counted in a
blind manner by two individuals using an Olympus
BX51 microscope (Center Valley, PA) and newCAST
software (Visiopharm, Hoersholm, Denmark). Conclu-
sions were drawn only when differences in counts
were less than 12% between individuals.
Statistical analysis
One- or two-way analysis of variance and Bonferroni’s
post-hoc analysis were used for statistical evaluation.
Treatment groups were expressed as the mean ± SEM.
An independent t test was used in cases where only two
means could be compared. A value of P < 0.05 was con-
sidered statistically significant.
Results
NF-κB p50 activity in response to LPS changes across the
lifespan
While decreased NF-κB p50 expression has been linked to
CNS disease [32], how aging affects NF-κB p50 function
in the brain is poorly understood. To test the possibility of
age-specific effects on NF-κB p50 activity, whole brain nu-
clear extract was collected from young (3-week-old) and
older (9-month-old) LPS-treated C57BL/6 mice and
NF-κB p50 DNA binding was assessed. Peripherally ad-
ministered LPS (IP) causes an inflammatory response
characterized by elevated circulating pro-inflammatory
cytokines that transfers to the brain resulting in microglial
activation, which has been implicated in neuropathology
[44, 47, 48]. The 9-month-old mice treated with LPS
displayed significantly lower levels of NF-κB p50 DNA
binding when compared to young LPS-treated mice (Fig. 1,
P < 0.05), supporting that NF-κB p50 activity in response
to pro-inflammatory triggers changes across the lifespan.
The consequences of this change in NF κB activity across
the lifespan, particularly a decrease in NF-κB p50 function,
are poorly understood.
Aging and loss of NF-κB p50 function synergistically
interact to amplify serum and brain TNFα
To address the effects of loss of NF-κB p50 function on
age-related increases in peripheral inflammation and
microglial priming, NF-κB p50+/+ and NF-κB p50−/− mice
in three age groups (1.5–3.0month old, 8.0–11.0month
old, and 16.0–18.0month old) were treated with LPS and
TNFα levels in serum and midbrain were evaluated at 3 h
post-injection. There were no significant differences in
baseline serum TNFα in any group tested (data not
shown). In response to LPS, serum TNFα levels in the
8.0–11.0 and 16.0–18.0month old age bracket were strik-
ingly elevated in NF-κB p50−/− mice (Fig. 2a, P < 0.05), but
Table 1 Primer Sequences
Gene Forward primer Reverse primer
COX-2 5′-TTGCTGGCCGGGTTGCTGG-3′ 5′-CAGGGAGAAGCGTTTGCGGT-3′
GAPDH 5′-AACTTTGGCATTGTGGAAGG-3′ 5′-ATCCACAGTCTTCTGGGTGG-3′
IL-1β 5′-TGAAGAAGAGCCCATCCTCTGTGA-3′ 5′-GGTCCGACAGCACGAGGCTT-3′
iNOS 5′-TCCAGAATCCCTGGACAAGCTGC-3′ 5′-TGCAAGTGAAATCCGATGTGGCCT-3′
TNFα 5′-GCCCACGTCGTAGCAAACCACC-3′ 5′-CCCATCGGCTGGCACCACTA-3′
COX-2 cyclooxygenase 2, GAPDH glyceraldehyde 3-phosphate dehydrogenase, IL-1β Interleukin 1β, iNOS inducible nitric oxide synthase, TNFα tumor necrosis
factor α
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Fig. 1 LPS-induced NF-κB p50 DNA binding changes across the
mouse lifespan. NF-κB p50 activity was assessed by determining
NF-κB p50 DNA binding in whole brain nuclear extract from 9-
month-old and 3-week-old C57BL/6 mice injected with LPS (5 mg/
kg, IP). Whole brain nuclear extract from the older mice injected
with LPS showed reduced DNA binding when compared to the
younger mice. Values are reported as mean percent of 3 week saline
control ± SEM. An asterisk indicates significant difference (P < 0.05)
from control. n = 4
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only the 16.0–18.0-month-old NF-κB p50−/− mice were
significantly higher than the genotype augmented TNFα
levels in 1.5–3.0-month-old NF-κB p50−/− mice (Fig. 2a, P
< 0.05). The midbrain exhibited a unique pattern, where
there was a trend for increased basal midbrain TNFα
levels with saline in 16–18-month-oldNF-κB p50−/− mice
(Fig. 2b, P =.099), suggesting that aging and loss of NF-κB
p50 function may mildly elevate basal levels of brain cyto-
kines. While the brain TNFα response to LPS was similar
in the 1.5–3.0 month old and 8.0–11.0-month-old NF-κB
p50−/− mice, the 16–18-month-old NF-κB p50−/− mice ex-
hibited synergistically higher levels of TNFα, when com-
pared to 1.5–3.0-month-old NF-κB p50−/− mice (Fig. 2c,
P < 0.05). Together, these results support that aging and
loss of NF-κB p50 function interact to augment inflamma-
tion in both the periphery and brain and that the CNS vul-
nerability to transfer of the synergistic peripheral effects
may elevate in middle age.
Aging and loss of NF-κB p50 function synergistically
interact to amplify midbrain IL-1β
To further characterize the effects of aging on NF-κB
p50-mediated priming of neuroinflammation, we assessed
levels of additional pro-inflammatory markers in
LPS-injected 1.5–3.0 (young adult) and 16–18 (middle
aged)-month-old NF-κB p50+/+ and NF-κB p50−/− mice.
An age-related increase in basal IL-1β expression was ob-
served in saline-treated mice, regardless of genotype
(Fig. 3a, P < 0.05). Peripheral LPS injection resulted in a
significant increase in brain IL-1β expression in
middle-aged NF-κB p50−/− mice versus both middle-aged
NF-κB p50+/+ mice and young adult NF-κB p50−/− mice
(Fig. 3b, P < 0.05). Consistent with our previous reports
documenting no differences in LPS-induced 3-h COX2
and iNOS gene expression in young adult NF-κB p50−/−
mice [7], genotype and age-related differences in brain
iNOS and COX2 expression were not observed (data not
shown). These findings indicate that aging and loss of
NF-κB p50 function interact to regulate IL-1β in the mid-
brain in middle-aged mice.
a
b
c
Fig. 2 Loss of NF-κB p50 function and aging synergistically interact
to augment serum and brain TNFα in middle-aged mice. NF-κB
p50+/+ and NF-κB p50−/− mice from three different age groups
(1.5–3.0 month old, 8.0–11.0 month old, and 16.0–18.0 month old)
were injected with saline or LPS (5 mg/kg, IP) to determine age-
related effects of loss of NF-κB p50 function on peripheral and
neuro-inflammation at 3 h post-injection. a Circulating TNFα protein
was measured by ELISA. Values are reported as mean expression ±
SEM. Midbrain TNFα mRNA levels were assessed following b saline
or c LPS treatment by quantitative RT-PCR. Values were normalized
to GAPDH using the 2−ΔΔCT method and are reported as mean
percent of saline control ± SEM. An asterisk indicates significant
difference (P < 0.05) from the 1.5–3.0-month-old group and a dagger
indicates a significant difference between mouse strains. n = 3–7
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Aging and NF-κB p50 affects microglia morphology and
overall number in the substantia nigra
To examine the age-related effects of loss of NF-κB p50
function on microglia, an analysis of microglia morph-
ology in the substantia nigra pars compacta (SNpc) of
young adult (1.5–3 months) and middle-aged (16–18
months) NF-κB p50+/+ and NF-κB p50−/− mice was per-
formed. While no differences in the number of resting
(Level 0) microglia were observed in saline-treated mice
(Fig. 4a), a significant decrease in the number of resting
(Level 0) microglia was observed in the SNpc of
LPS-treated middle-aged NF-κB p50−/− mice as com-
pared to LPS-treated middle-aged NF-κB p50+/+ mice
and young adult NF-κB p50−/− mice (Figs. 4b and 5, P <
0.05). Middle-aged saline-treated NF-κB p50−/− mice dis-
played a modest increase in basal levels of microglia with
mild morphological changes (Level 1) as compared to
middle-aged NF-κB p50+/+ mice; however this difference
was not significant (Fig. 4c, P = 0.06). Among LPS-treated
mice, numbers of microglia classified with a level 1
morphology were similar across age and genotype (Figs.
4d and 5). Middle-aged LPS-injected NF-κB p50−/− mice
showed significantly increased numbers of microglia exhi-
biting the level 2 morphology as compared to aged
LPS-injected NF-κB p50+/+ mice (Figs. 4f and 5, P < 0.05).
LPS-injected middle-aged NF-κB p50−/− mice showed an
increase in numbers of microglia with the level 3 morph-
ology, a morphology not observed in NF-κB p50+/+ mice.
However, significant differences were not observed (Figs.
4h and 5, P = .078). Few microglia classified as stage 2 or
stage 3 morphology were observed in the SNpc of
saline-treated mice (Fig. 4e and g). Additionally, both
NF-κB p50+/+ and NF-κB p50−/− mice displayed an
age-related increase in overall microglia number
(stages 0–3) in the SNpc with the largest age-related
increases in microglia number occurring in NF-κB
p50−/− mice (Table 2, P < 0.05). These findings dem-
onstrate an overall increase in microglia number with
age as well as an age-related increase in changes in
morphology in response to LPS in the absence of
NF-κB p50, which is characterized by lower numbers
of quiescent microglia and elevated numbers of
microglia displaying hypertrophic morphology.
Aging and loss of NF-κB p50 synergistically amplify IL-1β
and TNFα in microglia
To discern the age-related effects of loss of NF-κB p50
function specifically in microglia, young adult and
middle-aged mice of both genotypes were injected with
LPS and gene expression was evaluated in CD11b
microbead-isolated microglia at 3 h post-injection. Micro-
glia from saline-treated mice exhibited no significant dif-
ferences in basal TNFα nor IL-1β gene expression, except
that young adult NF-κB p50−/− mice had higher basal
levels of TNFα expression (Tables 3 and 4, P < 0.05).
Microglia isolated from the brains of middle-aged
LPS-injected NF-κB p50−/− mice showed significantly ele-
vated TNFα (Fig. 6a, P < 0.05) and IL-1β (Fig. 6b, P < 0.05)
expression as compared to young LPS-treated NF-κB
p50+/+ mice, supporting that loss NF-κB p50 function
amplifies microglial sensitivity to pro-inflammatory stim-
uli in the aging brain.
NF-κB p65 activation and expression decreases in middle-
aged mice
NF-κB p50−/− mice are missing the prototypical pro-in-
flammatory transcription factor NF-κB p50/p65, which is
traditionally associated with the induction of many
pro-inflammatory genes, including TNFα and IL-1β [34].
As such, the activation and expression characteristics of
a
b
Fig. 3 Loss of NF-κB p50 function and aging synergistically interact
to augment midbrain IL-1β in middle-aged mice. Young adult (1.5–
3.0 month old) and middle-aged (16.0–18.0 month old) NF-κB p50+/+
and NF-κB p50−/− mice were treated with a saline or b LPS (5 mg/
kg, IP), and brain tissue was collected at 3 h post-injection. IL-1β
expression in the brain was evaluated by quantitative RT-PCR. Values
are normalized to GAPDH using the 2−ΔΔCT method and are reported
as mean percent of NF-κB p50+/+ young adult saline control ± SEM. An
asterisk indicates significant difference (P < 0.05) from the 1.5–3.0-
month old group and a dagger indicates a significant difference
between mouse strains. n = 3
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NF-κB p65 were tested to begin to explore the signaling
necessary for the initiation and amplification of
pro-inflammatory factors in the absence of NF-κB p50.
Young adult and middle-aged NF-κB p50+/+ and NF-κB
p50−/− mice were injected with LPS and either whole brain
total protein or nuclear extract was collected at 3 h
a b
c d
e f
g h
Fig. 4 Aging NF-κB p50−/− mice have enhanced activated microglia morphology in response to peripheral LPS injection. Young adult (1.5–3.0
month old) and middle-aged (16.0–18.0 month old) NF-κB p50+/+ and NF-κB p50−/− mice were injected with saline or LPS (5 mg/kg, IP) to
evaluate loss of NF-κB p50 function on microglia morphology in vivo. IBA1 stained microglia within the substantia nigra pars compacta (in the
midbrain) were categorized into stages of activation ranging from resting (stage 0) to highly activated (stage 3). The relative number of microglia
at 3 h post-injection within stage 0 (a, b), stage 1(c, d), stage 2(e, f), and g & h stage 3(g, h) was quantified by the fractionator method. Values are
reported as mean cells/μm2 ± SEM of 3 coronal sections (40 μm) per animal. An asterisk indicates significant difference (P < 0.05) from control and
a dagger indicates a difference between mouse strains. n = 3
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post-injection. Analysis of NF-κB p65 DNA binding in nu-
clear extract found no differences in basal NF-κB p65 acti-
vation for any group tested in saline-treated mice (Fig. 7a,
p > 0.05). As expected, LPS injection resulted in a signifi-
cant increase in brain NF-κB p65 activation in both adult
and middle-aged NF-κB p50+/+ mice, but NF-κB p50−/−
mice failed to show any increase NF-κB p65 activity in re-
sponse to LPS (Fig. 7b, P < 0.05). Further, western blot
analysis of whole brain protein extract showed a signifi-
cant decrease in NF-κB p65 levels in middle-aged mice,
regardless of genotype (Fig. 7c, P < 0.05), suggesting that
drastic age-related and synergistic increases in microglial
priming may occur through signaling independent of the
prototypical NF-κB p50/p65 transcription factor.
Discussion
Microglia in the aging brain display a primed phenotype
characterized by increased basal pro-inflammatory cytokine
expression, heightened reactivity to pro-inflammatory stim-
uli, and resistance to regulation, which has been implicated
in the vulnerability of the aged brain to neurodegenerative
diseases [12, 13]. However, the molecular mechanisms driv-
ing microglia to a primed and dysregulated phenotype in
the aging brain are unclear. Previous reports implicate loss
of NF-κB p50 function due to disease [32], ROS [7], aging
[40, 42], and genetic deletion [7, 31], as a potential mechan-
ism that could prime the microglial pro-inflammatory re-
sponse [7, 31]. Here, we address the role of NF-κB p50 in
regulating microglia in the aging brain and reveal that (1)
NF-κB p50 activity in response to a pro-inflammatory trig-
gers changes across the lifespan, which decreases in older
mice; (2) aging synergistically amplifies pro-inflammatory
priming due to loss of NF-κB p50 function in microglia and
the brain in middle-aged mice; and (3) NF-κB p65 expres-
sion is reduced in the middle-aged brain and NF-κB p65
activity in response to LPS decreases in the middle-aged
NF-κB p50−/− brain, despite the presence of exaggerated
neuroinflammation.
Fig. 5 Representative images demonstrating augmented changes in microglia morphology in middle-aged NF-κB p50−/− mice. Young adult
(1.5–3.0 month old) and middle-aged (16.0–18.0 month old) NF-κB p50+/+ and NF-κB p50−/− mice were injected with saline or LPS (5 mg/kg, IP) to
evaluate loss of NF-κB p50 function on microglia morphology in vivo. Three coronal sections (40 μm) per animal containing the substantia nigra
pars compacta were stained with IBA1. Representative images are shown from the substantia nigra pars compacta at × 40 and the scale bar
depicts 50 μM. n = 3
Table 2 Microglia number. Cell counts in young adult and
middle-aged NF-κB p50+/+ and NF-κB p50−/− mice
Group Mean cells/10− 5 μm2 SEM P value
Young p50+/+ 6.145 0.134
Middle-aged p50+/+ 6.985* 0.294 .026
Young p50−/− 6.973 0.346
Middle-aged p50−/− 9.283* 0.587 .007
The relative number of microglia counted in all stages of morphology (0–3) in
the SNpc was quantified by the fractionator method. Values are reported as
mean cells/μm2 of 3 coronal sections (40 μm) per animal. *Significant
difference (P < 0.05) from young genotype-matched mice. n = 3
Table 3 TNFα mRNA expression in microglia isolated from
saline-treated control mice
Group TNFα expression SEM P value
Young p50+/+ 100.00 12.36
Young p50−/− 242.12* 42.35 < 0.05
Middle-aged p50+/+ 100.00 6.17
Middle-aged p50−/− 175.19 42.76
Young adult (1.5–3.0 month old) and middle-aged (16.0–18.0 month old) NF-κB
p50+/+ and NF-κB p50−/− mice were injected with saline, and isolation of
microglia from the whole brain with CD11b microbeads was performed at 3 h
post-injection. TNFα mRNA levels were evaluated by quantitative RT-PCR.
Values are normalized to GAPDH using the 2−ΔΔCT method. *Significant
difference (P < 0.05) between mouse strains. n = 3
Taetzsch et al. Journal of Neuroinflammation           (2019) 16:60 Page 8 of 13
NF-κB p50 is an important redox-sensitive regulator of
the microglial activation response, where oxidative modifi-
cation, including the free radical form of NF-κB p50, has
been associated with loss of NF-κB p50 function, augmen-
tation/priming of the late-stage pro-inflammatory re-
sponse, and vulnerability to chronic inflammation in
microglia and the brain [7]. While the NF-κB p50/p65
heterodimer is a prototypical activator of the pro-inflam-
matory response in many myeloid cells including micro-
glia, the NF-κB p50/p50 homodimer is a key repressor of
the pro-inflammatory response [49]. Recent studies using
NF-κB p50−/− mice indicate that NF-κB p50 is sufficient
but not necessary to induce microglial activation and neu-
roinflammation [7, 31]. Rather, the removal of
pro-inflammatory inhibition that allows the elevated and
chronic neuroinflammation has been implicated as the
critical consequence of loss of NF-κB p50 for pro-inflam-
matory function of key pro-inflammatory factors in the
brain [7, 31]. Importantly, the current study found higher
levels of TNFα, IL-1β, and microglial activation in re-
sponse to LPS in the brain of NF-κB p50−/− mice for all
ages investigated (Figs. 2, 3, 4, 5 and 6), as expected.
In the current study, we sought to discern how aging
impacts NF-κB p50 in the brain. Consistent with the
premise that oxidative stress increases in the aging brain
[28], that ROS impairs NF-κB p50 function in microglia
[7], and that aging in peripheral tissues is associated with
a loss of NF-κB p50 function [40, 42], we found that
9-month-old mice exhibited less NF-κB p50 DNA bind-
ing in the brain when compared to younger 3-week-old
mice (Fig. 1). While it should be noted that brain NF-κB
p50 DNA binding in young mice may be affected by dif-
ferences in developmental processes [37] and the mul-
tiple cell types in the brain, these age-specific effects in
NF-κB p50 activity support that loss of NF-κB p50 func-
tion may occur in the brain with aging, which could
contribute to the dysregulated pro-inflammatory pheno-
type in the aging brain.
We next sought to reveal how aging and loss of NF-κB
p50 function interact to regulate the pro-inflammatory
environment in the brain. Intraperitoneal LPS injections
result in elevated circulating cytokines, such as TNFα,
that cross the blood-brain barrier to activate microglia
and cause neuroinflammation [44], emphasizing the im-
portance of communication between the peripheral and
CNS immune systems for brain health [26]. Here, we
demonstrate that while loss of NF-κB p50 function
causes robustly elevated circulating LPS-induced TNFα
when compared to control mice, aging further aug-
mented (× 6 amplification) this already primed response
to a striking magnitude (x = 11,297 pg/mL TNFα). While
the excessive priming occurred as early as 8.0–11.0
months of age and continued to 16.0–18.0 months of
age with the serum (Fig. 2a), this type of priming was
only seen at the later ages (16.0–18.0 months) in the
brains of the NF-κB p50−/− mice (Fig. 2c), suggesting
that the brain’s vulnerability to the synergistic peripheral
pro-inflammatory response increases with age.
Consistent with our prior report in young adult mice
[7], loss of NF-κ B p50 function did not impact all
Table 4 IL-1β mRNA expression in microglia isolated from
saline-treated control mice
Group IL-1β SEM P value
Young p50+/+ 100.00 38.00
Young p50−/− 95.93 24.00
Middle-aged p50+/+ 100.00 12.30
Middle-aged p50−/− 120.00 57.40
Young adult (1.5–3.0 month old) and middle-aged (16.0–18.0 month old) NF-κB
p50+/+ and NF-κB p50−/− mice were injected with saline, and isolation of
microglia from the whole brain with CD11b microbeads was performed at 3 h
post-injection. IL-1β mRNA levels were evaluated by quantitative RT-PCR.
Values are normalized to GAPDH using the 2-ΔΔCT method. *Significant
difference (P < 0.05) between mouse strains. n = 3
a
b
Fig. 6 Loss of NF-κB p50 function and aging synergistically interact
to amplify TNFα and IL-1β in isolated microglia. Young adult (1.5–
3.0 month old) and middle-aged (16.0–18.0 month old) NF-κB p50+/+
and NF-κB p50−/− mice were injected with LPS (5 mg/kg, IP), and
isolation of microglia from the whole brain with CD11b microbeads
was performed at 3 h post-injection. Differences in a TNFα and b IL-
1β were evaluated by quantitative RT-PCR. Values are normalized to
GAPDH using the 2−ΔΔCT method and are reported as mean percent
of NF-κB p50+/+ young adult saline control ± SEM. An asterisk
indicates significant difference (P < 0.05) from the 1.5–3-month
group and a dagger indicates a difference between mouse
strains. n = 3
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Fig. 7 NF-κB p65 DNA expression and activity in aging and NF-κBp50−/− mice. Young adult (1.5–3.0 month old) and middle-aged (16.0–18.0
month old) NF-κB p50+/+ and NF-κB p50−/− mice were injected with saline or LPS (5 mg/kg, IP). Nuclear extract collected from whole brain tissue
at 3 h following a saline or b LPS injection was evaluated for NF-κB p65 DNA binding with ELISA. c Total NF-κB p65 protein in brain tissue at 3 h
post-injection was evaluated by western blot and normalized to GAPDH. d Representative image of NF-κB p65 and GAPDH western blot bands
used to calculate the total NF-κB p65 brain protein. Values are reported as mean percent of saline control ± SEM. An asterisk indicates a significant age
effect (P < 0.05) and a dagger indicates a significant difference between mouse strains (P < 0.05). n = 3
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pro-inflammatory mediators and preferentially aug-
mented TNFα and IL-1β at 3 h in response to intraperi-
toneal injection of LPS at all ages explored. Interestingly,
aging synergistically amplified the neuroinflammation
priming induced by loss of NF-κB p50 function as seen
in the midbrain (TNFα and IL-1β, Figs. 2c and 3b), iso-
lated adult microglia (TNFα and IL-1β, Fig. 6a and b),
and changed in microglia morphology in the substantia
nigra (Figs. 4 and 5). Thus, data indicate that aging and
loss of NF-κB p50 function interact to synergistically
augment LPS-induced peripheral inflammation, neuroin-
flammation, and more specifically, the microglial
pro-inflammatory response. However, these findings are
unable to differentiate how much of the amplified neu-
roinflammation is due to the augmented peripheral
pro-inflammatory response versus the sensitivity of the
microglia to a pro-inflammatory trigger.
To further characterize the role of NF-κB in this
age-induced synergistic response in the brain, we began
by investigating NF-κB p65 activity and expression in
the brain. Functional NF-κB p65 is present in NF-κB
p50−/− mice and has been previously implicated in com-
bination with other transcription factors to participate in
activation of pro-inflammatory genes [50], making
NF-κB p65 the most likely candidate for initiation and
amplification of neuroinflammation with age. Surpris-
ingly, NF-κB p65 total protein expression was lowered in
the brains of middle-aged mice, regardless of genotype
(Fig. 7). Further, while NF-κB p50+/+ mice exhibited an
LPS-induced increase in brain NF-κB p65 DNA binding
in both young and aging mice, the NF-κB p50−/− mice
revealed a decrease in LPS-induced NF-κB p65 DNA
binding, regardless of age (Fig. 7a and b). As such,
these findings indicate a break between age-induced
microglial priming in the brain and prototypical
pro-inflammatory signaling that supports the presence
of an unknown yet highly efficacious activator of
pro-inflammatory genes with the absence or decline
of NF-κB p50 and NF-κB p65.
Conclusions
In summary, increasing reports indicate that loss of
NF-κB p50 function in the brain may occur due to neu-
rodegenerative disease [32] and ROS [7] and that brain
NF-κB p50 activity in response to pro-inflammatory
stimuli changes across a lifetime (Fig. 1). Middle age is
an important time point in the life span to consider
when exploring the potential mechanisms that may
cause a pre-disposition to neurodegenerative diseases. In
the current study, we reveal that aging (middle age) and
loss of NF-κB p50 function interact to result in elevated
basal neuroinflammation and synergistically augment
microglial activation/neuroinflammation in response to a
peripheral pro-inflammatory trigger, such as LPS. This is
important because not only does it provide a possible ra-
tionale for the pro-inflammatory baseline in the aging
brain, but it may also offer insight as to why the aging
brain, even at middle age, may have a heightened re-
sponse to disease and pro-inflammatory stimuli. The
current study presents the hypothesis that it may be the
additional loss of NF-κB p50 function across the lifespan
that may be driving some of the age-specific vulnerabil-
ity to pro-inflammatory stimuli in the brain. In fact, data
reveal that a loss of function of both components of the
prototypical pro-inflammatory transcription factor
(NF-κB p50/p65) is associated with aging in the brain
and that this occurs concurrently with the augmented
pro-inflammatory response, pointing to a novel, un-
known, and robust mechanism responsible for aging-in-
duced neuroinflammation priming in middle-aged mice.
As such, it remains of significant importance that future
scientific inquiry focus on elucidating this unique dele-
terious signaling in an effort to identify potential
markers and therapeutic targets capable of modifying
the outcome of aging-related CNS diseases.
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